1Detano B G. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis, 1989, 14(2 Suppl 1) : 14-18.
3Fishbane S,Kowalski EA.The comparative safety of intravenous iron dextran,iron saccharate,and sodium ferric gluconate.Semin Dial,2000,13:381-384.
4Charytan C,Levin N,A1-Saloum M,et al.Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia:North American Clinical Trial.Am J Kidney Dis,2001,37:300-307.
5Michael B,Coyne DW,Fishbane S,et al.Sodium ferric gluconate complex in hemodialysis patients:adverse reactions compared to placebo and iron dextran.Kidney Int,2002,61:1830-1839.
6Silverstein SB,Rodgers GM.Parenteral iron therapy options.Am J Hematol,2004,76:74-78.
7Hamstra RD,Block MH,Schocket AL.Intravenous iron dextran in clinical medicine.JAMA,1980,243:1726-1731.
8Fishbane S,Ungureanu VD,Maesaka JK,et al.The safety of intravenous iron dextran in hemodialysis patients.Am J Kidney Dis,1996,28:529-534.
9Faich G,Strobos J.Sodium ferric gluconate complex in sucrose:safer intravenous iron therapy than iron dextrans.Am J Kidney Dis,1999,33:464-470.
10Lawrence R.Development and comparison of iron dextran products.PDA J Pharm Sci Technol,1998,52:190-197.
